These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 37254941)

  • 1. Comparing how well abrocitinib and dupilumab treat atopic dermatitis signs and symptoms: a plain language summary.
    Reich K; Thyssen JP; Blauvelt A; Eyerich K; Soong W; Rice ZP; Hong HC; Katoh N; Valenzuela F; DiBonaventura M; Bratt TA; Zhang F; Clibborn C; Rojo R; Valdez H; Kerkmann U
    Immunotherapy; 2023 Sep; 15(13):975-980. PubMed ID: 37254941
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing abrocitinib and dupilumab in the treatment of atopic dermatitis: a plain language summary.
    Bieber T; Simpson EL; Silverberg JI; Thaçi D; Paul C; Pink AE; Kataoka Y; Chu CY; DiBonaventura M; Rojo R; Antinew J; Ionita I; Sinclair R; Forman S; Zdybski J; Biswas P; Malhotra B; Zhang F; Valdez H
    Immunotherapy; 2022 Jan; 14(1):5-14. PubMed ID: 34775830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Abrocitinib in Patients with Severe and/or Difficult-to-Treat Atopic Dermatitis: A Post Hoc Analysis of the Randomized Phase 3 JADE COMPARE Trial.
    Simpson EL; Silverberg JI; Thyssen JP; Viguier M; Thaçi D; de Bruin-Weller M; Weidinger S; Chan G; DiBonaventura M; Biswas P; Feeney C; Koulias C; Cork MJ
    Am J Clin Dermatol; 2023 Jul; 24(4):609-621. PubMed ID: 37213005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial.
    Ständer S; Kwatra SG; Silverberg JI; Simpson EL; Thyssen JP; Yosipovitch G; Zhang F; Cameron MC; Cella RR; Valdez H; DiBonaventura M; Feeney C
    Am J Clin Dermatol; 2023 Jan; 24(1):97-107. PubMed ID: 36512175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapidity of Improvement in Signs/Symptoms of Moderate-to-Severe Atopic Dermatitis by Body Region with Abrocitinib in the Phase 3 JADE COMPARE Study.
    Alexis A; de Bruin-Weller M; Weidinger S; Soong W; Barbarot S; Ionita I; Zhang F; Valdez H; Clibborn C; Yin N
    Dermatol Ther (Heidelb); 2022 Mar; 12(3):771-785. PubMed ID: 35297025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure.
    Simpson EL; Silverberg JI; Nosbaum A; Winthrop K; Guttman-Yassky E; Hoffmeister KM; Egeberg A; Valdez H; Fan H; Farooqui SA; Chan G; Alderfer J; Romero W; Chittuluru K
    Am J Clin Dermatol; 2024 Jul; 25(4):639-654. PubMed ID: 38888681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial.
    Reich K; Thyssen JP; Blauvelt A; Eyerich K; Soong W; Rice ZP; Hong HC; Katoh N; Valenzuela F; DiBonaventura M; Bratt TA; Zhang F; Clibborn C; Rojo R; Valdez H; Kerkmann U
    Lancet; 2022 Jul; 400(10348):273-282. PubMed ID: 35871814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Magnitude and Time Course of Response to Abrocitinib for Moderate-to-Severe Atopic Dermatitis.
    Reich K; Lio PA; Bissonnette R; Alexis AF; Lebwohl MG; Pink AE; Kabashima K; Boguniewicz M; Nowicki RJ; Valdez H; Zhang F; DiBonaventura M; Cameron MC; Clibborn C
    J Allergy Clin Immunol Pract; 2022 Dec; 10(12):3228-3237.e2. PubMed ID: 36108923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abrocitinib versus Placebo or Dupilumab for Atopic Dermatitis.
    Bieber T; Simpson EL; Silverberg JI; Thaçi D; Paul C; Pink AE; Kataoka Y; Chu CY; DiBonaventura M; Rojo R; Antinew J; Ionita I; Sinclair R; Forman S; Zdybski J; Biswas P; Malhotra B; Zhang F; Valdez H;
    N Engl J Med; 2021 Mar; 384(12):1101-1112. PubMed ID: 33761207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported outcomes from the JADE COMPARE randomized phase 3 study of abrocitinib in adults with moderate-to-severe atopic dermatitis.
    Thyssen JP; Yosipovitch G; Paul C; Kwatra SG; Chu CY; DiBonaventura M; Feeney C; Zhang F; Myers D; Rojo R; Valdez H
    J Eur Acad Dermatol Venereol; 2022 Mar; 36(3):434-443. PubMed ID: 34779063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interpreting the Relationship Among Itch, Sleep, and Work Productivity in Patients with Moderate-to-Severe Atopic Dermatitis: A Post Hoc Analysis of JADE MONO-2.
    Yosipovitch G; Gooderham MJ; Ständer S; Fonacier L; Szepietowski JC; Deleuran M; Girolomoni G; Su JC; Bushmakin AG; Cappelleri JC; Feeney C; Chan G; Thorpe AJ; Valdez H; Biswas P; Rojo R; DiBonaventura M; Myers DE
    Am J Clin Dermatol; 2024 Jan; 25(1):127-138. PubMed ID: 37624488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 3 efficacy and safety of abrocitinib in adults with moderate-to-severe atopic dermatitis after switching from dupilumab (JADE EXTEND).
    Shi VY; Bhutani T; Fonacier L; Deleuran M; Shumack S; Valdez H; Zhang F; Chan GL; Cameron MC; Yin NC
    J Am Acad Dermatol; 2022 Aug; 87(2):351-358. PubMed ID: 35439608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
    Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
    Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
    Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
    Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of oral abrocitinib on signs, symptoms and quality of life among adolescents with moderate-to-severe atopic dermatitis: an analysis of patient-reported outcomes.
    Cork MJ; McMichael A; Teng J; Valdez H; Rojo R; Chan G; Zhang F; Myers DE; DiBonaventura M
    J Eur Acad Dermatol Venereol; 2022 Mar; 36(3):422-433. PubMed ID: 34743361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Abrocitinib in Combination With Topical Therapy in Adolescents With Moderate-to-Severe Atopic Dermatitis: The JADE TEEN Randomized Clinical Trial.
    Eichenfield LF; Flohr C; Sidbury R; Siegfried E; Szalai Z; Galus R; Yao Z; Takahashi H; Barbarot S; Feeney C; Zhang F; DiBonaventura M; Rojo R; Valdez H; Chan G
    JAMA Dermatol; 2021 Oct; 157(10):1165-1173. PubMed ID: 34406366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abrocitinib Provides Rapid and Sustained Improvement in Skin Pain and Is Associated with Improved Quality of Life Outcomes in Adult and Adolescent Patients with Moderate-to-Severe Atopic Dermatitis.
    Thyssen JP; Bewley A; Ständer S; Castro C; Misery L; Kim BS; Biswas P; Chan G; Myers DE; Watkins M; Alderfer J; Güler E; Silverberg JI
    Dermatology; 2024; 240(2):243-253. PubMed ID: 38081155
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abrocitinib: A New FDA-Approved Drug for Moderate-to-Severe Atopic Dermatitis.
    Perche PO; Cook MK; Feldman SR
    Ann Pharmacother; 2023 Jan; 57(1):86-98. PubMed ID: 35587593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abrocitinib efficacy and safety in patients with moderate-to-severe atopic dermatitis: Results from phase 3 studies, including the long-term extension JADE EXTEND study.
    Reich K; Silverberg JI; Papp KA; Deleuran M; Katoh N; Strober B; Beck LA; de Bruin-Weller M; Werfel T; Zhang F; Biswas P; DiBonaventura MD; Chan G; Johnson S; Farooqui SA; Kerkmann U; Clibborn C
    J Eur Acad Dermatol Venereol; 2023 Oct; 37(10):2056-2066. PubMed ID: 37335885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Laboratory Safety from a Randomized 16-Week Phase III Study of Dupilumab in Children Aged 6 Months to 5 Years with Moderate-to-Severe Atopic Dermatitis.
    Paller AS; Siegfried EC; Cork MJ; Wollenberg A; Arkwright PD; Gonzalez ME; Lockshin B; Chen Z; Bansal A; Levit NA; Prescilla R
    Paediatr Drugs; 2023 Jan; 25(1):67-77. PubMed ID: 36529811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.